

Supplementary figures and figure legends




Fig. S1 Transduction efficiencies of an FX-pretreated Ad vector in the neonatal liver.

Ad-L2 was mixed with human FX before administration. The mixture of Ad-L2 and human FX was administered *via* retro-orbital sinus at doses of  $5.9 \times 10^{11}$  IFU/kg for Ad-L2 and 1.1 mg/kg for human FX. Luciferase production (A) and Ad genome copy numbers (B) were examined in the neonatal liver 48 h after Ad vector administration. All values were normalized to 1 by the data of Ad-L2-administered neonatal mice.




Fig. S2 Ad vector-mediated transgene expression in the organs *via* retro-orbital sinus and tail vein administration.

Adult mice were administered Ad-L2 at a dose of  $5.9 \times 10^{11}$  IFU/kg *via* retro-orbital sinus and the tail vein. Luciferase production was examined in each organ 48 h after Ad vector administration.